3 Cannabis Penny Stocks For Biopharm Investors

Tuesday, April 6, 2021 | Thomas Hughes

There’s More To Cannabis Than The Recreational Market  

It’s hard to remember that there is more to the cannabis market than recreational use and smoking. The cannabis industry has its roots in medical cannabis and that is still a driving force of value today. Today’s list highlights three company’s whose business includes, if not focuses on, the health side of the industry, an industry that is expected to grow at a high 20 to 30% CAGR for the next several years. What makes these companies more attractive is that they trade for pennies compared to their mainstream biopharma cousins. 

Heritage Cannabis Completes Transformation 

Heritage Cannabis is a small medical cannabis company with business in the recreational and CBD markets as well. The company recently reported a dismal quarter that belied the underlying transformation. The company transitioned from wholesales to purely branded sales over the last quarter and that has had an impact on gross revenue. The Q1 gross revenue of $1.827 million is down 54% from the previous year because of it but this will be the last quarter of difficult comps. 

The company has made several acquisitions that will boost revenue and earnings and is on the brink of several initiatives paying off. Among them is an expansion into the U.S. market that includes the launch of three key medical products for the CBD and medical cannabis market. The 1st product slated for release is an AnthroCBD capsule later this month, the others are a sublingual strip and a topical cream all targeting skin conditions like eczema, psoriasis, and local pain. 

“As we move forward, we expect to see continued acceleration in both our medical and recreational product divisions with the addition of Premium 5 starting to have a material effect in Canada. Additionally, with our imminent launch in the multi-billion dollar U.S. market, and continued growth from our Pura Vida and Purefarma brands we expect to be well-positioned to drive further positive results and shareholder value,” said Clint Sharples, Chief Executive Officer of Heritage.

Three Cannabis Penny Stocks For Biopharm Investors

HempFusion Wellness, Inc Tackles The Edible CBD Market 

HempFusion (OTCMKTS: CBDHF) is a health and wellness company focused on CBD products you can eat or consume. Among the 48 SKUs are tinctures, FDA-approved topicals, Dr./Caregiver product lines, and probiotics. The company just released its earnings as well delivering more than $3.82 million in revenue for 2020 or up 26.5% from 2019. Based on a recent CBD industry report the U.S. market alone is expected to grow by 65% to $25 billion over the next four years so we expect this pace to continue if not accelerate. 

With its products on sale in all 50 states, HempFusion is not only a leader in the CBD market but an attractive takeover target for company’s seeking growth, expansion, or entry into the U.S. market. Shares of the stock are trading near the post-IPO low and may head lower although there is risk in that outlook. Not only is the CBD market and this company expected to grow at a robust double-digit CAGR but the market in shares of CBDHF is oversold and beamish momentum is waning. 

Three Cannabis Penny Stocks For Biopharm Investors

Can-Fite Cannabis Compound Inhibits Liver Cancer 

Can-Fite (NYSEAmerican: CANF) is an Israel-based clinical-stage biopharma researching small-molecule therapeutic products for treating cancers, inflammatory diseases, and other ailments. Among its many pipeline products are a range of CBD-based treatments and one has been proven in a proof-of-concept trial. The company showed that a CBD-rich cannabis fraction was able to inhibit liver cancer growth by interacting with receptors known to activate cancer cell growth. The news, surprisingly, did not move much on the news but we think they will in time. And that doesn’t take into account the company’s two main pipeline drugs, Piclidenoson and Namodenoson.

Three Cannabis Penny Stocks For Biopharm Investors

Featured Article: Straddles

7 Penny Stocks That Don’t Care About Robinhood

By the time you read this Vladimir Tenev, the CEO of the trading app Robinhood, will be testifying in front of Congress. The company’s role in the GameStop (NYSE:GME) short squeeze will be called into question.

However, the real issue at stake is the right of traders to buy and sell the equities of their choice. In the case of Robinhood, some traders are buying a lot of penny stocks. While definitions vary, penny stocks are generally considered stocks that are trading for less than $10 per share. These stocks are largely ignored by the investment community.

One reason is that many of these stocks are cheap for a reason. For example, the company may have a business model that is out of date. In other cases, they operate in a very small, niche market that doesn’t drive a lot of revenue.

And most of these stocks are ignored by the investment community. They simply aren’t considered significant enough to spend time debating.

But some penny stocks do have the attention of Wall Street. And they’re being largely ignored by the day trading community. The focus of this special presentation is to direct you to penny stocks that have a story that the “smart money” thinks will eventually be trading at much higher prices.

And that’s why you should be looking at them now.

View the "7 Penny Stocks That Don’t Care About Robinhood".

Companies Mentioned in This Article

CompanyMarketRank™Current PricePrice ChangeDividend YieldP/E RatioConsensus RatingConsensus Price Target
Hempfusion Wellness (CBDHF)0.0$1.30flatN/AN/AN/AN/A
Compare These Stocks  Add These Stocks to My Watchlist 

MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.